Sign in or create an account to add this stock to your watchlist.
About Avadel Pharmaceuticals (NASDAQ:AVDL)
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVDL
CUSIPN/A
Phone636-449-1830
Debt
Debt-to-Equity Ratio1.28
Current Ratio2.66
Quick Ratio2.59
Price-To-Earnings
Trailing P/E Ratio21.77
Forward P/E Ratio-4.35
P/E GrowthN/A
Sales & Book Value
Annual Sales$172.74 million
Price / Sales1.44
Cash Flow$0.4652 per share
Price / Cash14.51
Book Value$2.37 per share
Price / Book2.85
Profitability
EPS (Most Recent Fiscal Year)$0.31
Net Income$68.27 million
Net Margins18.96%
Return on Equity-13.95%
Return on Assets-4.22%
Miscellaneous
Employees180
Outstanding Shares36,740,000
Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions
What is Avadel Pharmaceuticals' stock symbol?
Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."
How will Avadel Pharmaceuticals' stock buyback program work?
Avadel Pharmaceuticals announced that its Board of Directors has approved a stock buyback program on Wednesday, March 28th 2018, which permits the company to buyback $7,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 2.7% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.
How were Avadel Pharmaceuticals' earnings last quarter?
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) released its quarterly earnings results on Wednesday, May, 2nd. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.08. The company earned $33.29 million during the quarter, compared to the consensus estimate of $29.60 million. Avadel Pharmaceuticals had a negative return on equity of 13.95% and a net margin of 18.96%. View Avadel Pharmaceuticals' Earnings History.
When is Avadel Pharmaceuticals' next earnings date?
What price target have analysts set for AVDL?
3 equities research analysts have issued 12-month price targets for Avadel Pharmaceuticals' shares. Their predictions range from $14.00 to $30.00. On average, they anticipate Avadel Pharmaceuticals' share price to reach $22.6667 in the next year. View Analyst Ratings for Avadel Pharmaceuticals.
Who are some of Avadel Pharmaceuticals' key competitors?
Some companies that are related to Avadel Pharmaceuticals include Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Reata Pharmaceuticals (RETA), NuCana (NCNA), Arrowhead Pharmaceuticals (ARWR), Assembly Biosciences (ASMB), UroGen Pharma (URGN), Deciphera Pharmaceuticals (DCPH), Rhythm Pharmaceuticals (RYTM), Collegium Pharmaceutical (COLL), Theratechnologies (THERF) and Rocket Pharmaceuticals (RCKT).
Who are Avadel Pharmaceuticals' key executives?
Avadel Pharmaceuticals' management team includes the folowing people:
- Mr. Michael S. Anderson, CEO & Director (Age 69)
- Mr. Michael F. Kanan, CFO & Sr. VP (Age 55)
- Mr. Phillandas T. Thompson J.D., M.B.A., Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
- Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 61)
- Dr. David Monteith Ph.D., VP of R&D (Age 54)
Has Avadel Pharmaceuticals been receiving favorable news coverage?
Headlines about AVDL stock have been trending somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Avadel Pharmaceuticals earned a news sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the company an impact score of 46.41 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Avadel Pharmaceuticals' major shareholders?
Avadel Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.92%), BlackRock Inc. (1.28%), GSA Capital Partners LLP (0.79%), California Public Employees Retirement System (0.23%), Alps Advisors Inc. (0.13%) and Trexquant Investment LP (0.11%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Francis Fildes, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.
Which major investors are selling Avadel Pharmaceuticals stock?
AVDL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and BlackRock Inc.. Company insiders that have sold Avadel Pharmaceuticals company stock in the last year include Craig R Stapleton, Guillaume Cerutti and Healthcare Master Fun Broadfin. View Insider Buying and Selling for Avadel Pharmaceuticals.
Which major investors are buying Avadel Pharmaceuticals stock?
AVDL stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Trexquant Investment LP, O Shaughnessy Asset Management LLC, Alps Advisors Inc. and California Public Employees Retirement System. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.
How do I buy shares of Avadel Pharmaceuticals?
Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avadel Pharmaceuticals' stock price today?
One share of AVDL stock can currently be purchased for approximately $6.75.
How big of a company is Avadel Pharmaceuticals?
Avadel Pharmaceuticals has a market capitalization of $238.84 million and generates $172.74 million in revenue each year. The company earns $68.27 million in net income (profit) each year or $0.31 on an earnings per share basis. Avadel Pharmaceuticals employs 180 workers across the globe.
How can I contact Avadel Pharmaceuticals?
Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]
MarketBeat Community Rating for Avadel Pharmaceuticals (AVDL)
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Avadel Pharmaceuticals (NASDAQ:AVDL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Avadel Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.6667, suggesting that the stock has a possible upside of 235.80%. The high price target for AVDL is $30.00 and the low price target for AVDL is $14.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.6667 | $22.6667 | $24.6667 | $25.00 |
| Price Target Upside: | 235.80% upside | 210.93% upside | 171.96% upside | 179.02% upside |
Avadel Pharmaceuticals (NASDAQ:AVDL) Consensus Price Target History
Avadel Pharmaceuticals (NASDAQ:AVDL) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Avadel Pharmaceuticals (NASDAQ:AVDL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Avadel Pharmaceuticals (NASDAQ AVDL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.31%
Institutional Ownership Percentage: 69.55%
Avadel Pharmaceuticals (NASDAQ AVDL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/15/2017 | Craig R Stapleton | Director | Buy | 140,000 | $8.67 | $1,213,800.00 | |  |
| 12/7/2017 | Michael S. Anderson | CEO | Buy | 5,000 | $8.86 | $44,300.00 | | |
| 11/27/2017 | Craig R Stapleton | Director | Sell | 254,265 | $9.35 | $2,377,377.75 | 253,413 | |
| 9/21/2017 | Peter J Thornton | Director | Buy | 5,155 | $9.74 | $50,209.70 | 5,155 | |
| 9/14/2017 | Sandra L. Hatten | Insider | Buy | 2,100 | $9.36 | $19,656.00 | | |
| 9/13/2017 | Phillandas T. Thompson | Insider | Buy | 5,000 | $9.36 | $46,800.00 | | |
| 9/12/2017 | Craig R Stapleton | Director | Buy | 20,000 | $9.52 | $190,400.00 | 507,678 | |
| 9/12/2017 | Greg J Divis | Insider | Buy | 10,600 | $9.32 | $98,792.00 | 10,600 | |
| 9/12/2017 | Michael S. Anderson | CEO | Buy | 4,000 | $9.80 | $39,200.00 | | |
| 6/23/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 261,000 | $10.68 | $2,787,480.00 | | |
| 6/15/2017 | Guillaume Cerutti | Director | Sell | 26,560 | $10.46 | $277,817.60 | 23,440 | |
| 5/22/2017 | Craig R Stapleton | Director | Buy | 31,013 | $9.85 | $305,478.05 | 507,678 | |
| 5/19/2017 | Michael S Anderson | CEO | Buy | 2,500 | $10.00 | $25,000.00 | 225,750 | |
| 11/29/2016 | Craig R Stapleton | Director | Buy | 20,000 | $10.79 | $215,800.00 | 519,678 | |
| 11/21/2016 | Michael S. Anderson | CEO | Buy | 2,000 | $10.64 | $21,280.00 | | |
| 9/22/2016 | Francis Fildes | Director | Sell | 15,000 | $13.45 | $201,750.00 | 15,000 | |
| 9/2/2016 | Michael S. Anderson | CEO | Buy | 2,000 | $14.12 | $28,240.00 | | |
| 9/1/2016 | Craig R Stapleton | Director | Buy | 10,000 | $13.52 | $135,200.00 | 519,678 | |
| 8/26/2016 | Craig R Stapleton | Director | Buy | 20,000 | $13.76 | $275,200.00 | 509,678 | |
| 8/22/2016 | Michael S. Anderson | CEO | Buy | 5,000 | $14.30 | $71,500.00 | | |
| 5/16/2016 | Craig R Stapleton | Director | Buy | 27,228 | $9.21 | $250,769.88 | 507,263 | |
| 5/12/2016 | Michael S Anderson | CEO | Buy | 5,000 | $8.84 | $44,200.00 | 134,250 | |
| 3/22/2016 | Phillandas T Thompson | Insider | Buy | 10,000 | $11.10 | $111,000.00 | 20,000 | |
| 3/18/2016 | Michael S Anderson | CEO | Buy | 5,000 | $11.04 | $55,200.00 | 129,250 | |
| 3/18/2016 | Sandra L Hatten | VP | Buy | 3,000 | $11.01 | $33,030.00 | 3,000 | |
| 3/14/2016 | Craig R Stapleton | Director | Buy | 100,000 | $10.39 | $1,039,000.00 | 482,450 | |
| 3/14/2016 | Michael S Anderson | Insider | Buy | 10,000 | $9.74 | $97,400.00 | 124,250 | |
(Data available from 1/1/2013 forward)
Avadel Pharmaceuticals (NASDAQ AVDL) News Headlines
| Source: |
|
Avadel Pharmaceuticals (NASDAQ:AVDL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Avadel Pharmaceuticals (NASDAQ:AVDL) Income Statement, Balance Sheet and Cash Flow Statement
Avadel Pharmaceuticals (NASDAQ AVDL) Stock Chart for Saturday, May, 26, 2018
Loading chart…
